New pharmacological treatments for the management of obesity

Current Gastroenterology Reports

Volumn 16, Issue 6, 2014, Pages

  Hurt, Ryan T ^a,b   Varayil, Jithinraj Edakkanambeth ^a,c   Ebbert, Jon O ^a  

^a MAYO CLINIC   (United States)

^b University of Louisville School of Medicine   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Lorcaserin; Obesity; Orlistat; Phentermine; Sibutramine

Indexed keywords

AMFEPRAMONE; BENZPHETAMINE; DEXFENFLURAMINE; FENFLURAMINE; LORCASERIN; METHAMPHETAMINE; PHENDIMETRAZINE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; QYSMIA; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; BENZAZEPINE DERIVATIVE; DRUG COMBINATION; FRUCTOSE; TOPIRAMATE;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ANXIETY; BACKACHE; BLOATING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONSTIPATION; DEPRESSION; DIAPHORESIS; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPHORIA; ELEVATED BLOOD PRESSURE; FECES INCONTINENCE; HEADACHE; HEART ARREST; HEART INFARCTION; HEART PALPITATION; HEART VALVE REGURGITATION; HUMAN; HYPERTENSION; HYPOPHAGIA; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIVER DISEASE; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRECANCER; PULMONARY HYPERTENSION; RESTLESSNESS; REVIEW; RHINOPHARYNGITIS; SATIETY; SEIZURE; STEATORRHEA; TACHYCARDIA; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VALVULAR HEART DISEASE; WEIGHT REDUCTION; XEROSTOMIA; ANALOGS AND DERIVATIVES; DRUG APPROVAL; DRUG COMBINATION; TREATMENT OUTCOME;

ANTI-OBESITY AGENTS; BENZAZEPINES; DRUG APPROVAL; DRUG COMBINATIONS; FRUCTOSE; HUMANS; OBESITY; PHENTERMINE; TREATMENT OUTCOME;

EID: 84900558046     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-014-0394-0     Document Type: Review

References (72)

1. Organization WH. Obesity and overweight: Fact sheet. In: WHO Media centre WHO. 2013. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed February 27, 2014 2014.
2. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491-7. doi:10.1001/jama.2012. 39. The most recent obesity epidemiology data in the United States.
3. Prevention CfDCa. Morbidity and mortality weekly report. CDC, Atlanta, GA. 2010. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm59e0803a1.htm http://www.cdc.gov/mmwr/pdf/wk/mm59e0803.pdf. Accessed February 27 2014.
4. Hurt RT, Frazier TH, McClave SA, Kaplan LM. Obesity epidemic: overview, pathophysiology, and the intensive care unit conundrum. JPEN J Parenter Enteral Nutr. 2011;35(5):4S-13S. doi:10.1177/0148607111415110.
5. Allison DB, Downey M, Atkinson RL, Billington CJ, Bray GA, Eckel RH, et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring). 2008;16(6):1161-77. (Pubitemid 351770522)
6. Beal E. The pros and cons of designating obesity a disease: the new AMA designation stirs debate. Am J Nurs. 2013;113(11):18-9. doi:10.1097/01.NAJ. 0000437102.45737.c7.
7. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res. 1998;6(2):51S-209S.
8. Jensen MD, Ryan DH, Apovian CM, Loria CM, Ard JD, Millen BE, et al. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.11.004. Recently updated ambulatory obesity management guideline.
9. Serdula MK, Mokdad AH, Williamson DF, Galuska DA, Mendlein JM, Heath GW. Prevalence of attempting weight loss and strategies for controlling weight. JAMA. 1999;282(14):1353-8. (Pubitemid 29483193)
10. Hurt RT, Kulisek C, Buchanan LA, McClave SA. The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. Gastroenterol Hepatol. 2010;6(12):780-92.
11. Kruger J, Galuska DA, Serdula MK, Jones DA. Attempting to lose weight: specific practices among U.S. adults. Am J Prev Med. 2004;26(5):402-6. (Pubitemid 38698260)
12. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859-73.
13. DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356(21):2176-83. doi:10.1056/NEJMct067019. (Pubitemid 47010843)
14. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes - 3-year outcomes. N Engl J Med. 2014. doi:10.1056/NEJMoa1401329.
15. Zimmet P, Alberti KG. Surgery or medical therapy for obese patients with type 2 diabetes? N Engl J Med. 2012;366(17):1635-6. doi:10.1056/NEJMe1202443.
16. Khan LK, Serdula MK, Bowman BA, Williamson DF. Use of prescription weight loss pills among U.S. adults in 1996-1998. Ann Intern Med. 2001;134(4):282-6.
17. Kaplan LM. Pharmacologic therapies for obesity. Gastroenterol Clin North Am. 2010;39(1):69-79. doi:10.1016/j.gtc.2010.01.001.
18. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med. 2012;367(17):1577-9. doi:10.1056/NEJMp1211277.
19. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther. 1992;51(5):642-6.
20. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581-8. doi:10.1056/NEJM199708283370901. (Pubitemid 27360757)
21. Bray GA. A concise review on the therapeutics of obesity. Nutrition. 2000;16(10):953-60.
22. Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007;356(1):6-9. doi:10.1056/NEJMp068265.
23. Mitchell P, Smythe G. Hormonal responses to fenfluramine in depressed and control subjects. J Affect Disord. 1990;19(1):43-51. (Pubitemid 20141160)
24. FDA USFaDA. FDA announces withdrawal fenfluramine and dexfenfluramine (Fen-Phen). In: withdrawal of fenphen. FDA. 1997. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm. Accessed February 27 2014.
25. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs. 1998;56(6):1093-124. (Pubitemid 29010230)
26. Hainer V, Hainerova IA. Do we need anti-obesity drugs? Diabetes Metab Res Rev. 2012;28 Suppl 2:8-20. doi:10.1002/dmrr.2349.
27. Lindholm A, Bixo M, Bjorn I, Wolner-Hanssen P, Eliasson M, Larsson A, et al. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2008;89(5):1221-8. doi:10.1016/j.fertnstert.2007.05.002. (Pubitemid 351671719)
28. Garcia-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvarez LM. Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther. 2006;28(5):770-82. doi:10.1016/j.clinthera. 2006.05.008. (Pubitemid 44173053)
29. Sanchez-Reyes L, Fanghanel G, Yamamoto J, Martinez-Rivas L, Campos-Franco E, Berber A. Use of sibutramine in overweight adult Hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther. 2004;26(9):1427-35. doi:10.1016/j.clinthera.2004.09. 017. (Pubitemid 39572156)
30. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996;4(3):263-70. (Pubitemid 126690229)
31. Rossner S. [The trial that killed a drug]. Lakartidningen. 2010;107(39):2339.
32. Williams G. Withdrawal of sibutramine in Europe. BMJ. 2010;340:c824. doi:10.1136/bmj.c824.
33. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med. 2005;143(5):380-5. (Pubitemid 41266610)
34. Hendricks EJ, Greenway FL. A study of abrupt phentermine cessation in patients in a weight management program. Am J Ther. 2011;18(4):292-9. doi:10.1097/MJT.0b013e3181d070d7.
35. Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Rev Cardiovasc Ther. 2010;8(12):1777-801. doi:10.1586/erc.10.125.
36. Bray GA. Drug insight: appetite suppressants. Nat Clin Pract Gastroenterol Hepatol. 2005;2(2):89-95. doi:10.1038/ncpgasthep0092. (Pubitemid 40790155)
37. Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens. 2014. doi:10.1097/HJH.0000000000000145.
38. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39(1):32-41. doi:10.1002/1098-2396(20010101).
39. Bays H, Rodbard HW, Schorr AB, Gonzalez-Campoy JM. Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr Treat Options in Cardiovasc Med. 2007;9(4):259-71. (Pubitemid 47181092)
40. Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011;19(12):2351-60. doi:10.1038/oby.2011.94.
41. Hendricks EJ, Srisurapanont M, Schmidt SL, Haggard M, Souter S, Mitchell CL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes (Lond). 2014;38(2):292-8. doi:10.1038/ijo.2013. 74ijo201374.
42. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000;20(3):270-9. (Pubitemid 30140745)
43. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281(3):235-42. (Pubitemid 29058112)
44. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9(2):160-7.
45. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25(7):1123-8. (Pubitemid 41071161)
46. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167-72. (Pubitemid 28327800)
47. Veerman L. Orlistat reduces weight but its cost-effectiveness remains unclear. Evid-Based Nurs. 2013;16(2):56-7. doi:10.1136/eb-2012-100958.
48. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194-9. doi:10.1136/bmj.39385.413113.25. (Pubitemid 350273303)
49. Leblanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(7):434-47.
50. Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med. 2011;171(7):703-4. doi:10.1001/archinternmed.2011.103.
51. Morris M, Lane P, Lee K, Parks D. An integrated analysis of liver safety data from orlistat clinical trials. Obesity Facts. 2012;5(4):485-94. doi:10.1159/000341589.
52. Orlistat: hepatitis and oxalate nephropathy. Prescrire international. 2012;21(125):71.
53. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21(8):1288-94. (Pubitemid 28365685)
54. FDA. FDA approves Belviq to treat some overweight or obese adults. In: FDA NEWS RELEASE. 2012. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm309993.htm?utm-campaign=Google2&utm-source= fdaSearch&utm-medium=website&utm-term=lorcaserin&utm-content=4. Accessed February 27 2014.
55. Fleming JW, McClendon KS, Riche DM. New obesity agents: lorcaserin and phentermine/topiramate. Ann Pharmacother. 2013;47(7-8):1007-16. doi:10.1345/aph.1R779.
56. Katsidoni V, Apazoglou K, Panagis G. Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine. Psychopharmacol. 2011;213(2-3):337-54. doi:10.1007/s00213-010-1887-7.
57. Bubar MJ, Cunningham KA. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem. 2006;6(18):1971-85. (Pubitemid 44524471)
58. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325(2):577-87. doi:10.1124/jpet.107.133348. (Pubitemid 351574813)
59. Weissman NJ, Sanchez M, Koch GG, Smith SR, Shanahan WR, Anderson CM. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6(4):560-7. doi:10.1161/CIRCIMAGING.112.000128.
60. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245-56. doi:10.1056/NEJMoa0909809.
61. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067-77. doi:10.1210/jc.2011-1256. A large study demonstrating a significant weight loss benefit of lorcaserin.
62. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426-36. doi:10.1038/oby.2012.66oby201266. study demonstrating the effect of lorcaserin for weight loss in patients with type 2 diabetes mellitis.
63. U.S Department of Justice DEAOodc. Schedules of controlled substances: placement of lorcaserin into schedule IV. Drug Enforcement Administration, Department of Justice. Springfield. 2012. http://www.deadiversion.usdoj.gov/fed- regs/rules/2012/fr1219.htm. Accessed April, 7 2014.
64. Cameron F, Whiteside G, McKeage K. Phentermine and topiramate extended release (Qsymia): first global approval. Drugs. 2012;72(15):2033-42. doi:10.2165/11640860-000000000-00000.
65. Malgarini RB, Pimpinella G. Phentermine plus topiramate in the treatment of obesity. Lancet. 2011;378(9786):125-6. doi:10.1016/S0140-6736(11)61080-5. author reply 6-7.
66. FDA USFaDA. FDA approves weight-management drug Qsymia. FDA. 2012. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm312468.htm. Accessed February 27 2014.
67. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11(6):722-33. doi:10.1038/oby.2003.102. (Pubitemid 41151598)
68. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord : J Int Assoc Study of Obesity. 2004;28(11):1399-410. doi:10.1038/sj.ijo.0802783. (Pubitemid 39481843)
69. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41 Suppl 1:S3-9.
70. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-52. doi:10.1016/S0140-6736(11)60205-5. The combinations of phentermine and topiramate was found to have significant weight reduction in overweight/ obese subjects.
71. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20(2):330-42. doi:10.1038/oby.2011.330.
72. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297-308. doi:10.3945/ajcn.111.024927. A two year extension to the CONQUER study which did not demonstrate any cardiovascular abnormality in the phentermine/topiramate compared to placebo.